Fubotv earnings beat by $0.10, revenue topped estimates
Aprea Therapeutics Inc (NASDAQ:APRE)’s stock has faced a significant downturn, touching a 52-week low of $2.15. The biopharmaceutical company, which focuses on developing and commercializing novel cancer therapies, has seen its shares plummet over the past year, with a decline of 63.1%. Despite the current market cap of just $12 million, InvestingPro analysis suggests the stock is undervalued, with analyst price targets ranging from $11 to $20. This substantial drop has alarmed investors and analysts alike, as the company grapples with the pressures of a challenging market and the high stakes of drug development. While the company maintains a strong current ratio of 7.01 and holds more cash than debt, InvestingPro data reveals it’s quickly burning through cash. The current price level serves as a critical juncture for Aprea Therapeutics, as stakeholders closely monitor its ability to recover and advance its clinical programs. Get access to 5 more exclusive InvestingPro Tips to better understand APRE’s financial position.
In other recent news, Aprea Therapeutics has announced a collaboration with MD Anderson Cancer Center to advance preclinical research on its WEE1 kinase inhibitor, APR-1051, focusing on head and neck squamous cell carcinoma. This partnership aims to evaluate the efficacy of APR-1051, especially in combination with immune checkpoint inhibitors, to support future clinical trials. Additionally, Aprea has expanded its patent portfolio, which includes its ATR inhibitor program with the lead compound ATRN-119, backed by a robust patent estate set to expire between 2035 and 2044. The company’s intellectual property also covers the WEE1 kinase inhibitor program, with patents potentially extending exclusivity to 2043. H.C. Wainwright has reaffirmed its Buy rating and set a $20 price target for Aprea, citing the company’s recent clinical pipeline updates and projected milestones. The firm noted Aprea’s focus on advancing its precision oncology programs, APR-1051 and ATRN-119, both in clinical trials for solid tumors. Aprea’s management expects to have approximately $22.8 million in cash by the end of 2024, which they believe will support operations for at least the next 12 months. Both APR-1051 and ATRN-119 have reported no hematologic toxicity thus far in their respective trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.